Compare
Vanda Pharmaceuticals Inc. vs IDEAYA Biosciences, Inc. vs Puma Biotechnology, Inc. vs Anaptysbio, Inc
| Latest fiscal year | Vanda Pharmaceuticals Inc. VNDA | IDEAYA Biosciences, Inc. IDYA | Puma Biotechnology, Inc. PBYI | Anaptysbio, Inc ANAB |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2025-12-31 | 2025-12-31 | 2025-12-31 |
| Revenue | $216.10M | $218.71M | $228.37M | $234.60M |
| Revenue growth (YoY) | +8.7% | n/m | -0.9% | +157.0% |
| Gross margin | n/a | n/a | 74.5% (computed) | n/a |
| Operating margin | -70.0% | -72.8% | 16.3% | 20.4% |
| Net margin | -102.0% | -52.0% | 13.6% | -5.6% |
| Net income | -$220.47M | -$113.70M | $31.11M | -$13.23M |
| EPS (Diluted) | -$3.74 | -$1.28 | $0.61 | -$0.46 |
| Operating cash flow | -$109.44M | -$71.10M | $41.80M | $19.70M |
| Free cash flow | -$110.44M | -$73.47M | $41.73M | $19.61M |
| Cash & equivalents | $84.85M | $112.83M | $29.64M | $238.20M |
| Total assets | $488.95M | $1.11B | $216.30M | $364.39M |
| Total liabilities | $161.76M | $86.39M | $85.96M | n/a |
| Shareholders' equity | $327.19M | $1.02B | $130.34M | $37.21M |
| Return on year-end equity | -67.4% | -11.1% | 23.9% | -35.6% |
| Shares outstanding | 59.10M | 87.80M | 50.41M | 28.02M |
Revenue, most recent five fiscal years
| Fiscal year | Vanda Pharmaceuticals Inc. | IDEAYA Biosciences, Inc. | Puma Biotechnology, Inc. | Anaptysbio, Inc |
|---|---|---|---|---|
| Latest | $216.10M Ended 2025-12-31 | $218.71M Ended 2025-12-31 | $228.37M Ended 2025-12-31 | $234.60M Ended 2025-12-31 |
| 1 year earlier | $198.77M Ended 2024-12-31 | $7.00M Ended 2024-12-31 | $230.47M Ended 2024-12-31 | $91.28M Ended 2024-12-31 |
| 2 years earlier | $192.64M Ended 2023-12-31 | $23.39M Ended 2023-12-31 | $235.64M Ended 2023-12-31 | $17.16M Ended 2023-12-31 |
| 3 years earlier | $254.38M Ended 2022-12-31 | $50.93M Ended 2022-12-31 | $228.03M Ended 2022-12-31 | $10.29M Ended 2022-12-31 |
| 4 years earlier | $268.68M Ended 2021-12-31 | $27.94M Ended 2021-12-31 | $253.16M Ended 2021-12-31 | $63.17M Ended 2021-12-31 |